Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype  by Cicoira, Mariantonietta et al.
Failure of Aldosterone Suppression Despite
Angiotensin-Converting Enzyme (ACE)
Inhibitor Administration in Chronic Heart
Failure Is Associated With ACE DD Genotype
Mariantonietta Cicoira, MD,* Luisa Zanolla, MD,* Andrea Rossi, MD,* Giorgio Golia, MD,*
Lorenzo Franceschini, MD,* Giulio Cabrini, MD,† Alberto Bonizzato, BSC,† Maristella Graziani, PHD,‡
Stefan D. Anker, MD, PHD,§\ Andrew J. S. Coats, DM, FACC,§ Piero Zardini, MD*
Verona, Italy; London, United Kingdom; and Berlin, Germany
OBJECTIVES The objective of this study was to assess whether the angiotensin-converting enzyme (ACE)
gene insertion/deletion (I/D) polymorphism influences the adequacy of the neurohormonal
response to ACE inhibitors in patients with chronic heart failure (CHF).
BACKGROUND The renin-angiotensin-aldosterone system (RAAS) plays an important role in the patho-
physiology of CHF, and aldosterone levels closely relate to outcome in patients with CHF.
Angiotensin-converting enzyme inhibitors suppress the RAAS, but a significant proportion
of patients exhibit elevated serum levels of aldosterone despite long-term administration of
apparently adequate doses of these agents.
METHODS We prospectively studied 132 patients with CHF (ejection fraction ,45%) receiving
long-term therapy with ACE inhibitors for over six months. Patients taking aldosterone
antagonists were excluded from the study. “Aldosterone escape” was defined as being present
when plasma aldosterone levels were above the normal range in our laboratory (.42 nmol/L).
Patients were then divided into two subgroups according to the presence (group 1) or absence
(group 2) of aldosterone escape. Genotype analysis for the ACE I/D polymorphism was
performed by polymerase chain reaction.
RESULTS The prevalence of aldosterone escape in our patients was 10% (13/132). The two groups of
patients did not differ regarding the dose of ACE inhibitor, diuretics and their renal function.
There was a statistically significant different distribution of genotypes between the two
groups, with a higher proportion of DD genotype in group 1 compared with group 2 (62%
vs. 24%, p 5 0.005).
CONCLUSIONS Patients with CHF with aldosterone escape have a higher prevalence of DD genotype
compared with patients with aldosterone within the normal limits. Angiotensin-converting
enzyme gene polymorphism contributes to the modulation and adequacy of the neurohor-
monal response to long-term ACE-inhibitor administration in CHF. (J Am Coll Cardiol
2001;37:1808–12) © 2001 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitors reduce
both morbidity and mortality in patients with chronic heart
failure (CHF) (1–3). Neurohormonal activation in CHF is
closely related to the outcome of treated patients with heart
failure (4), and the progression of the disease itself has been
largely attributed to neurohormonal factors (5). It has been
hypothesized, therefore, that the effects of ACE inhibitors
on patient survival might be due more to hormone suppres-
sion than to hemodynamic improvement (6). Nevertheless,
the renin-angiotensin-aldosterone system (RAAS) is not
uniformly suppressed during therapy with ACE inhibitors.
In fact, it has been reported that up to 20% of patients with
CHF have elevated plasma levels of aldosterone despite
long-term ACE-inhibitor administration (7–9). This “aldo-
sterone escape” carries important clinical consequences be-
cause aldosterone levels are an important prognostic marker
in patients with CHF. This observation is further supported
by the Randomized Aldactone Evaluation Study (RALES),
which showed that aldosterone antagonism with spirono-
lactone strongly reduces mortality in patients with severe
CHF (10). Nevertheless, the mechanisms underlying in-
complete aldosterone suppression with ACE inhibitors have
not yet been adequately investigated. An insertion/deletion
polymorphism, consisting of a 287 base pair (bp) sequences
in intron 16 of the ACE gene, has been reported to predict
approximately half of the variance in serum ACE levels
among individuals (11). Homozygotes for the deletion allele
(DD) have higher serum (11) and tissue (12) ACE levels
and activity compared with heterozygotes (ID) and ho-
mozygotes (II). Angiotensin-converting enzyme gene DD
polymorphism is also known to be a risk factor for the
development of dilated cardiomyopathy and ischemic heart
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disease (13). However, a possible role of ACEs in deter-
mining the neurohormonal response to ACE inhibitors has
never been investigated. We hypothesized that different
ACE genotypes, because of their variable intrinsic enzy-
matic activities, might partially account for the different
degree of aldosterone suppression observed during long-
term ACE-inhibitor therapy. Therefore, we focused our
investigation on whether the DD genotype might be asso-
ciated preferentially with aldosterone escape in patients with
CHF who were undergoing long-term ACE-inhibitor
treatment.
METHODS
Patients. Between May 1999 and February 2000, we eval-
uated 175 consecutive patients with CHF as a result of
idiopathic dilated cardiomyopathy, ischemic or valvular
heart disease. All had been followed by our heart failure
outpatient clinic. All patients had a left ventricular ejection
fraction (LVEF) ,45%, as assessed by echocardiography.
Every patient had been in a stable clinical condition for at
least three months before the study. Each patient was
receiving standard therapy for CHF, including an ACE
inhibitor at the highest tolerated dose for at least six
months. None of the patients had renal failure (creatinine
.150 mmol/L), liver or lung disease, malignant hyperten-
sion, inducible ischemia or recent (less than six months)
myocardial infarction. Forty patients undergoing therapy
with aldosterone antagonists and three with malignancies
were excluded from further study. The final study group
included 132 patients. Various ACE inhibitors were used.
The dose of ACE inhibitor was, therefore, expressed as a
percentage of the maximal recommended dosage (14). The
dose of diuretics was expressed in equivalent frusemide
dosage. The protocol of the study was in accordance with
the ethical standards of the Helsinki Declaration and was
approved by the Ethics Committee of the Ospedale Civile
Maggiore of Verona. Every patient provided written in-
formed consent before being enrolled in the study.
Hormonal measurements. Venous blood samples were
drawn after a 30 min supine rest in a fasting state between
8 and 9 AM For plasma aldosterone measurement, 4 mL of
blood were collected into an evacuated glass tube containing
EDTA (50 mL, 4.9%) and e-aminocaproic acid (3,000
KIE). After centrifugation, the plasma sample was frozen at
280°C until the analysis was performed (maximum eight
months). The concentrations of aldosterone were measured
by a sandwich radioimmunoassay (Biochem Immuno Sys-
tem, Verona, Italy) at the Laboratory of Clinical Chemistry
of our hospital. “Aldosterone escape” was prospectively
defined as the presence of aldosterone plasma concentra-
tions above the upper limit of the reference range (.42
nmol/L). Patients were subsequently subdivided into two
groups according to the presence (group 1) or absence
(group 2) of aldosterone escape.
ACE genotyping. The polymerase chain reaction (PCR)
method used to establish the ACE genotype was previously
described (15). The procedure used to prepare DNA for
PCR from whole blood was based on the one described by
Walsh et al. (16) for forensic material. Putative DD geno-
types were further confirmed by using the ACE 2 primer
(17), which eliminates mistyping that can occur with a
two-primer system (11). The PCR results were scored by
two independent investigators unaware of patient identity.
Statistics. All continuous variables are reported as mean 6
1 SD. Comparisons between groups were made by the
Student t test for unpaired data for continuous variables and
by the chi-square test for categorical variables; for the latter,
subgroup comparisons were performed by using the Brandt
and Snedecor test. A p value ,0.05 was considered statis-
tically significant.
RESULTS
Clinical and demographic characteristics of the study pa-
tients are summarized in Table 1. The majority of patients
were men (n 5 113; 86%). The mean age was 62 6 9 years
(range 35 to 77), and the mean LVEF was 34% 6 9%. Most
of the patients were in New York Heart Association
functional class II (n 5 59; 45%) or III (n 5 42, 32%) and
diagnosed with an ischemic etiology (n 5 84; 64%); 46
(35%) had idiopathic dilated cardiomyopathy and two (1%)
had primary valvular heart disease.
The frequency of aldosterone escape observed in 13
patients, according to our definition, was 10%. There were
no statistically significant differences in the demographics,
clinical and laboratory characteristics between the two
groups (Table 1). In particular, the two groups had similar
renal function, and both frequency and dosage of ACE
inhibitors, diuretics and beta-adrenergic blocking agents
were comparable.
The genotype was DD in 37 subjects, ID in 72 subjects
and II in 23 subjects. The frequencies of D and I alleles were
55% and 45%, respectively. The observed frequencies of the
DD, ID and II genotypes did not significantly differ from
those predicted by the Hardy-Weinberg equilibrium (28%
vs. 31%, 55% vs. 50% and 17% vs. 19%, respectively) and
were similar to those of previous reports (18). In group 1,
there was a higher frequency of DD genotype compared
with group 2 (62% vs. 24%, p 5 0.005). In group 1, no
patient had II genotype compared with 23 patients (17%) in
group 2. Details about genotype distribution in the two
groups are given in Figure 1.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CHF 5 chronic heart failure
D 5 deletion
I 5 insertion
LVEF 5 left ventricular ejection fraction
PCR 5 polymerase chain reaction
RAAS 5 renin-angiotensin-aldosterone system
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DISCUSSION
In this study we found that patients with aldosterone escape
had a significantly higher prevalence of DD genotype
compared with patients without escape. The frequency of
DD genotype in patients with aldosterone escape was more
than twofold compared with patients with normal aldoste-
rone levels, and every patient with II genotype had adequate
aldosterone suppression according to our definition. Our
results, therefore, suggest a possible role of ACE gene
polymorphism in the modulation of the RAAS after long-
term ACE inhibition in patients with CHF.
Aldosterone escape in CHF. Elevated plasma aldosterone
levels are associated with a higher mortality rate in patients
with CHF as are elevated levels of catecholamines, renin
and angiotensin II (1). The Cooperative North Scandina-
vian Enalapril Survival (CONSENSUS) trial showed that,
in patients with severe CHF with above-median plasma
aldosterone levels, the six-month mortality rate was signif-
icantly higher than it was in patients who had below-
median levels (1). Furthermore, when levels of aldosterone
were reduced, there was a concomitant reduction in the
mortality rate (19). Therefore, it has been hypothesized that
the well-established effects of ACE inhibitors on survival in
patients with CHF are more due to the neurohormonal
suppression than to the hemodynamic effects (5). One of the
therapeutic targets during long-term ACE inhibition in
patients with CHF should, therefore, be the aldosterone
suppression. Nevertheless, it has been described that, in a
considerable number of patients with CHF, aldosterone
production still occurs despite long-term ACE inhibition
(8,20). This evidence provided the background for the
RALES study, which showed that the aldosterone antago-
nist spironolactone, when added to conventional therapy
with ACE inhibitors, substantially reduced both morbidity
and mortality in patients with severe CHF (10). Moreover,
aldosterone has several harmful effects on heart and circu-
lation: it promotes sodium and fluid retention and enhances
urinary potassium and magnesium excretion, and it also
stimulates myocardial fibrosis, contributes to vasoconstric-
tion both indirectly and by modulating endothelial function;
additionally, it contributes to baroreflex depression and
potentiates the effects of cathecolamines (21). In general,
therefore, because ACE inhibitors do not completely sup-
press aldosterone production, there are several reasons why
this hormone is a potential problem in patients with CHF.
ACE gene polymorphism. Recent results suggests that
genetic variants in the components of the RAAS may be
involved in the pathophysiology of cardiovascular diseases.
The observation that approximately 50% of the inter-
individual variability of plasma ACE is attributable to a
major gene polymorphism (15,22) led to the description of
an I/D polymorphism of the ACE gene. This polymor-
phism consists of the presence or absence of a 287-bp DNA
Table 1. Clinical Characteristics of 132 Patients With Chronic Heart Failure Divided According
to the Presence or Absence of Aldosterone “Escape”
All Patients
(n 5 132)
“Escape”
(n 5 13)
No “Escape”
(n 5 119)
p
Value
Age (yr) 62 6 9 63 6 10 62 6 9 NS
NYHA functional class
I–II (%) 78 (59) 6 (46) 72 (61) NS
III–IV (%) 54 (41) 7 (54) 47 (39) NS
Men (%) 113 (86) 11 (85) 102 (86) NS
Ischemic heart disease (%) 84 (64) 10 (77) 74 (62) NS
% ACE inhibitor, maximal dose 50 (25–100) 50 (12.5–100) 50 (25–100) NS
Beta-blockers (%) 91 (69) 12 (92) 79 (66) NS
Diuretics (%) 113 (86) 12 (92) 101 (85) NS
Frusemide equivalent dose (mg) 31 (25–50) 50 (25–100) 25 (25–50) NS
S-creatinine (mmol/L) 101 6 27 106 6 27 100 6 27 NS
S-potassium (mmol/L) 4.3 6 0.3 4.3 6 0.3 4.3 6 0.4 NS
S-sodium (mmol/L) 140 6 3 139 6 3 140 6 3 NS
LVEF (%) 34 6 9 33 6 8 34 6 9 NS
P-aldosterone (nmol/L) 0.24 (0.19–0.31) 0.50 (0.43–0.60) 0.23 (0.18–0.28) —
Values are reported as mean 6 SD, median (interquartile range) or number (%).
ACE 5 angiotensin-converting enzyme; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association.
Figure 1. Genotype distribution of 132 chronic heart failure patients with
and without aldosterone escape despite long-term treatment with
angiotensin-converting enzyme inhibitors. Results are reported as percent-
ages of total (graph) and absolute numbers (table). D 5 deletion; DD 5
deletion allele; I 5 insertion; ID 5 heterozygotes; II 5 homozygotes.
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fragment in intron 16 and is associated with serum (11) and
cardiac tissue (23) ACE levels. The mean plasma ACE
levels in DD subjects are about twice those of II subjects,
with heterozygotes ID having intermediate levels (11). The
DD genotype has also been reported to be a risk factor for
myocardial infarction (24), to be associated with an in-
creased mortality rate in dilated cardiomyopathy (25) and
with the development of left ventricular hypertrophy in
normal subjects (26). The ACE genotype has been reported
as being a significant predictor of the ACE inhibitor’s effect
in normotensive subjects (27). In patients with CHF, a
significant relation between the pressure response to capto-
pril administration and ACE genotype has been shown,
with the greater blood pressure decrease in the II patients
(28). Nevertheless, a possible role of ACE gene polymor-
phism in determining RAAS modulation after ACE-
inhibitor therapy in patients with CHF has never been
assessed. In this syndrome, the RAAS is activated, and,
therefore, the effects of ACE gene polymorphism on the
system regulation might be amplified.
Relationship between ACE gene polymorphism and al-
dosterone escape. We found a significantly higher fre-
quency of DD genotype in patients with aldosterone escape
compared with those without escape (62% vs. 24%; p 5
0.005). Furthermore, no II patient had aldosterone escape,
showing that in this group of patients ACE-inhibitor
response is adequate. On the other hand, 22% of patients
with DD genotype had aldosterone escape. Therefore, we
hypothesize that the latter group could particularly benefit
from aldosterone antagonist or angiotensin II receptor
antagonist therapy. Patients with and without aldosterone
escape had otherwise similar clinical characteristics, includ-
ing renal function, LVEF, dose of ACE inhibitors and
diuretics, and the only difference was the distribution of
ACE genotype. This observation supports a possible role of
ACE gene polymorphism in determining serum aldosterone
levels. Consequently, this polymorphism could influence the
inhibitory effect of ACE inhibitors on aldosterone produc-
tion beyond other well-known regulatory mechanisms.
Study limitations. We observed a 10% frequency of aldo-
sterone escape, which is lower than those previously re-
ported. There are two possible explanations for this appar-
ent discrepancy: first, as a cut-off value to define escape we
chose the upper limit of the normal range of our laboratory,
while other authors used the mean aldosterone level of
healthy volunteers (7) or other arbitrary methods (8). Many
patients in these studies may have been defined as having
aldosterone escape, despite aldosterone levels within normal
limits. Conversely, we considered all patients with aldoste-
rone levels below the upper limit of the normal range as not
having escape. Secondly, we excluded patients who were
being treated with aldosterone antagonists, and, therefore,
the true prevalence of the escape phenomenon in our
patients with CHF might be underestimated. However, we
did not seek to describe the prevalence of escape but rather
to identify a selected group of patients suitable for studying
the effects of ACE genotype on aldosterone production.
Conclusions. In this study, we found that the frequency of
aldosterone escape in patients with CHF receiving long-
term ACE-inhibitor treatment is significantly higher in
patients having DD genotype compared with those having
ID and II genotype. The D/D patients who are already
being treated might particularly benefit from drugs like
aldosterone antagonists or angiotensin II receptor antago-
nists or the association of two drugs. Therefore, in this
specific subgroup of patients, medical therapy has to be
optimized and maybe guided by hormonal measurements.
Prospective, randomized studies on larger populations are
needed to assess the relative role of each group of drugs
according to the ACE gene polymorphism. The challenge
for the future might be the “right therapy for the right
genotype.”
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